CUVITRU - Ig subcutaneous human 20%
IISR Protocol
Phase 2 mab active
Quick answer
CUVITRU - Ig subcutaneous human 20% for COPD Exacerbation Acute is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- COPD Exacerbation Acute
- Phase
- Phase 2
- Modality
- mab
- Status
- active